Regeneron Pharmaceuticals, Inc. (regn)
REGN Financials
| Trailing P/E | 19.88 |
| Forward P/E | 13.17 |
| Price/Sales | 5.31 |
| Price/Book | 2.54 |
| Market cap | $82.55B |
| Avg volume | 760190.0 |
| Shares outstanding | 101137842.0 |
Start Free — open REGN in Vest Terminal
Access live data, filings, ownership, and analysis for Regeneron Pharmaceuticals, Inc..
Regeneron Pharmaceuticals, Inc. FAQ
What does Regeneron Pharmaceuticals, Inc. (REGN) do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and…
What is REGN's P/E ratio?
Regeneron Pharmaceuticals, Inc. has a trailing P/E of 19.88× based on publicly available market data.
Does REGN pay a dividend?
Indicated dividend yield: 0.5%. Confirm ex-dates and payout history in Vest Terminal.
What sector is REGN in?
Regeneron Pharmaceuticals, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is REGN's market capitalization?
Approximate market cap: $82.55B.
What are the main risks for REGN?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of REGN?
Potential positives include revenue growth of 16.7% year-over-year, gross margin of 44.5% supports competitive unit economics.
Where can I get analyst estimates for REGN?
Public analyst price targets and consensus for Regeneron Pharmaceuticals, Inc. are on the free /stocks/regn/estimates page. Deeper estimate history and models are available in Vest Terminal.